SOLICITATION NOTICE
B -- HPV Blood Sample testing
- Notice Date
- 8/4/2010
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100163-KM
- Archive Date
- 9/3/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB), plans to procure on a sole source basis with Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany for services regarding the study of Human papillomavirus (HPV) antigen seroconversion in anogenital cancers and controls. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 541690 and the business size standard is $7 M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be twelve (12) months from date of award. The Hormonal and Reproductive Epidemiology Branch conducts research to identify groups at high risk of cancer, clarify the natural history of various cancers, understand the interactive effects of genetic and environmental factors on cancer risk, and elucidate biologic mechanisms of carcinogenesis. Human papillomavirus (HPV) infections are very common among young sexually active women. About 13-15 HPV types are considered to be carcinogenic and persistent infections may lead to the formation of precancers in a subset of women. The determinants of seroconversion are unknown and previous data are mainly restricted to the L1 antigens of HPV16 and HPV18. Early published validation studies have been very promising, showing strong associations of HPV6 with genital warts and HPV16 with cervical neoplasia. Little is known about multi-antigen seroconversion to a broad spectrum of HPV genotype, and whether the patterns of type- and antigen-specific seroconversion differ by population, cancer site, or histologic subtype. The purpose of the current procurement is to test 4118 HPV blood specimens. The laboratory of Michael Pawlita at the German Cancer Research Center, Heidelberg, has developed a reliable high throughput multiplex assay to measure antibody responses against multiple HPV proteins, including the 8 most frequent carcinogenic types (HPV16, 18, 31, 33, 35, 45, 52, and 58) and the two most important HPV genotypes (6 and 11) for genital warts. Currently, there is no other assay available that can measure antibodies directed against the L1, E6, and E7 proteins from carcinogenic, genital wart HPV genotypes and beta HPV type 5. The German Cancer Research Center is the only known source capable of performing the required analyses. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 19, 2010. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Karri Mares, Contract Specialist at maresk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-­­­­­100163-KM on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100163-KM/listing.html)
- Record
- SN02228808-W 20100806/100804235204-0b3bfceac49c8ad03492cf6865c71662 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |